Hepatic HIF2α modulates extra-hepatic disease-associated phenotypes during metabolic dysfunction-associated steatotic liver disease
Lorenz M.W. Holzner, Rosa M. Korpershoek, Youguo Niu, Anna Cochrane, Paula M. Darwin, Julia Babuta, Areesha Nazeer, Cecilia Castro, Alice P. Sowton, Alice E. Knapton, Benjamin D. Thackray, Julian Leether Griffin, Zoe Hall, Dino A. Giussani, Rob C. I. Wüst, Andrew J. Murray
This study investigates the role of hepatic HIF2α in MASLD, finding that its deletion leads to extra-hepatic complications like cardiac dysfunction and lean mass loss without protecting against liver disease progression.
bioRxiv · May 5, 2026 · PreprintPhysiology